The impact of direct-to-consumer personal genomic testing on perceived risk of breast, prostate, colorectal, and lung cancer: findings from the PGen study

Table 1 Sample sizes, stratified by analysis and cancer type

Sample definition	Breast (Women only)	Prostate (Men only)	Colorectal	Lung
Available survey responses	700	454	1154	1154
Eligible survey responses^a	649	388	1082	1080
2 W linear regression^b	576	354	969	966
6 M linear regression^c	565	343	947	945
Longitudinal analysis^d	500	314	847	844

2 W 2-week follow-up, 6 M 6-month follow-up
^aNo missing data for cancer-specific genetic risk result or baseline perceived risk; no reported cancer-specific diagnosis during data collection period
^bEligible survey responses, with available data for 2 W perceived risk
^cEligible survey responses, with available data for 6 M perceived risk
^dEligible survey responses, with available data for both 2 W and 6 M perceived risk